HAOHAI BIOTEC(06826)
Search documents
昊海生科(688366) - H股公告:翌日披露报表

2025-11-25 10:00
FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別: 股票 狀態: 新提交 公司名稱: 上海昊海生物科技股份有限公司(於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2025年11月25日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司(「香港聯交所」)證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露,必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06826 | 說明 | H 股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 事件 | | 已發行股份(不包括庫存股份)變動 | | 庫存股份變動 | 每股發行/出售 ...
昊海生物科技(06826)11月25日斥资259.18万港元回购9.37万股

智通财经网· 2025-11-25 09:31
智通财经APP讯,昊海生物科技(06826)发布公告,于2025年11月25日斥资259.18万港元回购9.37万股。 ...
昊海生物科技(06826.HK)11月25日耗资259.18万港元回购9.37万股

Ge Long Hui· 2025-11-25 09:31
格隆汇11月25日丨昊海生物科技(06826.HK)发布公告,2025年11月25日耗资259.18万港元回购9.37万 股,回购价格每股27.5-27.8港元。 ...
昊海生物科技(06826) - 翌日披露报表

2025-11-25 09:21
FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別: 股票 狀態: 新提交 公司名稱: 上海昊海生物科技股份有限公司(於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2025年11月25日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司(「香港聯交所」)證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露,必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06826 | 說明 | H 股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 事件 | | 已發行股份(不包括庫存股份)變動 | | 庫存股份變動 | 每股發行/出售 ...
昊海生科涨2.13%,成交额3115.29万元,主力资金净流入172.61万元
Xin Lang Zheng Quan· 2025-11-25 05:55
Core Viewpoint - The stock price of Haohai Biological Technology Co., Ltd. has experienced a decline of 15.47% year-to-date, with a slight recovery observed on November 25, where it rose by 2.13% to reach 50.38 CNY per share, indicating potential market interest despite recent downturns [2][1]. Company Overview - Haohai Biological Technology, established on January 24, 2007, and listed on October 30, 2019, is located in Shanghai and specializes in the research, production, and sales of medical devices and pharmaceuticals [2]. - The company's revenue composition includes: 44.12% from medical beauty and wound care products, 28.18% from ophthalmic products, 17.39% from orthopedic products, 8.46% from anti-adhesion and hemostatic products, and 1.86% from other products [2]. Financial Performance - For the period from January to September 2025, Haohai Biological reported a revenue of 1.899 billion CNY, reflecting a year-on-year decrease of 8.47%, while the net profit attributable to shareholders was 305 million CNY, down 10.63% year-on-year [2]. - The company has distributed a total of 891 million CNY in dividends since its A-share listing, with 557 million CNY distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders increased by 7.44% to 8,388, with an average of 0 shares held in circulation per shareholder [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 5.6048 million shares, an increase of 2.617 million shares compared to the previous period [3]. Market Activity - On November 25, the stock saw a trading volume of 31.1529 million CNY, with a turnover rate of 0.32%, and a net inflow of main funds amounting to 1.7261 million CNY [1].
智通港股回购统计|11月25日





智通财经网· 2025-11-25 01:13
Summary of Key Points Core Viewpoint - A total of 36 companies conducted share buybacks on November 24, 2025, with Tencent Holdings (00700) leading in both the number of shares repurchased and the total amount spent on buybacks. Group 1: Buyback Details - Tencent Holdings (00700) repurchased 1.022 million shares for a total of 636 million yuan, representing 0.825% of its total share capital for the year [1][2]. - China COSCO Shipping (01919) repurchased 3 million shares for 40.35 million yuan, accounting for 1.604% of its total share capital [2]. - China International Marine Containers (02039) repurchased 4.8904 million shares for 35.9467 million yuan, which is 1.530% of its total share capital [2]. Group 2: Other Notable Buybacks - China Feihe (06186) repurchased 7.233 million shares for 29.9668 million yuan, representing 1.969% of its total share capital [2]. - Sinopec Limited (00386) repurchased 4.054 million shares for 17.7861 million yuan, which is 0.150% of its total share capital [2]. - Pacific Basin Shipping (02343) repurchased 5 million shares for 12.757 million yuan, accounting for 1.555% of its total share capital [2]. Group 3: Smaller Buybacks - MONGOL MINING (00975) repurchased 390,000 shares for 3.6551 million yuan, which is 0.124% of its total share capital [2]. - Miniso Group (09896) repurchased 866,800 shares for 31.938 million yuan, representing 0.372% of its total share capital [2]. - Weigao Group (01066) repurchased 40,000 shares for 211,600 yuan, accounting for 4.379% of its total share capital [3].
昊海生科(688366) - H股公告:翌日披露报表

2025-11-24 10:15
呈交日期: 2025年11月24日 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別: 股票 狀態: 新提交 公司名稱: 上海昊海生物科技股份有限公司(於中華人民共和國註冊成立的股份有限公司) 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司(「香港聯交所」)證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露,必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06826 | 說明 H 股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份(不包括庫存股份)變動 | | | 庫存股份變動 | | | | | 事件 ...
昊海生物科技11月24日斥资99.22万港元回购3.61万股

Zhi Tong Cai Jing· 2025-11-24 09:54
昊海生物科技(06826)发布公告,于2025年11月24日,该公司斥资99.22万港元回购3.61万股股份,回购 价格为每股27.26-27.6港元。 ...
昊海生物科技(06826)11月24日斥资99.22万港元回购3.61万股

智通财经网· 2025-11-24 09:21
智通财经APP讯,昊海生物科技(06826)发布公告,于2025年11月24日,该公司斥资99.22万港元回购3.61 万股股份,回购价格为每股27.26-27.6港元。 ...
昊海生物科技(06826.HK)11月24日耗资99.22万港元回购3.61万股

Ge Long Hui· 2025-11-24 09:18
格隆汇11月24日丨昊海生物科技(06826.HK)发布公告,2025年11月24日耗资99.22万港元回购3.61万股, 回购价格每股27.26-27.6港元。 ...